Avoiding Common Pitfalls in the IND and CTA Submission Process

[Fill out the form below to register]

Abstract: When planning an Investigational New Drug (IND) or Clinical Trial Authorization (CTA) submission, navigating FDA, EMA, and other regulations can be challenging and creating scientifically-sound strategies are essential. As submissions expand to multiple countries during later phase trials, greater challenges can arise if not prepared with knowledge of the requirements, proper time management, and defined roles for the team towards approval. 

Join us as experts in project management, medical writing, and regulatory operations discuss best practices for a successful submission process from start to finish. 

Attendees will learn:

  • Efficiencies for multi-country submissions 
  • Essential steps in pre-submission planning 
  • Timeline management and potential pitfalls 
  • How to define roles and responsibilities to avoid delays or confusion 
  • Structure and content of the submissions at various stages of development 
  • Navigating the country–specific regulatory requirements 
  • Post-submission maintenance and responsibilities 

Presenters:

Jessica Reed, PhD, Senior Manager, Project and Account Management  

Nicole Northrop, PhD, Manager, Regulatory and Medical Writing 

Allison Ward, MSA, MSEd, Senior Manager, Regulatory Operations 

Avoiding Common Pitfalls in the IND and CTA Submission Process

Register for the webinar

Suggested For You

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry